Condition: Crohn's Disease · Sponsor: Assistance Publique - Hôpitaux de Paris
This research is a multicenter French randomized and single blinded phase III clinical trial evaluating two treatment strategies among Crohn's disease (CD) patients. The main objective is to assess if the addition of Crohn's Disease Exclusion Diet (CDED) to ongoing standard medication is superior to reduce the rate of relapses over 12 months compared to standard medication alone in children/adolescents with unstable CD responding with remission after a 2-months course of CDED
This description comes directly from the study's public registry record.
Franck Ruemmele, MD, PhD · +33 (0)1 44 49 25 16 · frank.ruemmele@aphp.fr
Prissile Bakouboula, PhD · +33 (0)1 71 19 64 94 · prissile.bakouboula@aphp.fr
Always discuss trial participation with your own doctor first.
| Hôpital Femme mère enfant, CHU Lyon - Service Hépato-gastroentérologie et Nutrition pédiatrique | Bron, France | Recruiting |
| CHU Caen Normandie - Service de Gastroentérologie pédiatrique | Caen, France | Recruiting |
| Hôpital de la Timone, AP-HM - Service de Gastroentérologie pédiatrique | Marseille, France | Recruiting |
| Hôpital Necker-Enfants malades - Service de Gastroentérologie pédiatrique | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04777656